NCT00001088View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

February 28, 2001

Study Completion Date

February 28, 2001

Conditions
HIV Infections
Interventions
BIOLOGICAL

APL 400-047

DRUG

Bupivacaine hydrochloride

Trial Locations (4)

14642

Univ of Rochester Med Ctr, Rochester

35294

Univ of Alabama at Birmingham, Birmingham

37232

Vanderbilt Univ Hosp, Nashville

98144

Univ of Washington / Pacific Med Ctr, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001088 - A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers | Biotech Hunter | Biotech Hunter